From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Vaccine Against HPV-16 and, Possibly, Cervical Cancer

A vaccine against human papillomavirus type 16 protected young women from persistent infection with this cervical cancer-related virus.

Cervical cancer is the second-ranking cause of cancer deaths in women worldwide. Almost all cases of cervical cancer are associated with human papillomavirus (HPV) infection, particularly HPV-16, which is present in nearly 50% of cases.

In an industry-funded study, a U.S. multicenter team randomized 2392 young women to receive 3 doses of an intramuscular vaccine that contained HPV-16 virus-like particles (not live virus) or placebo. Sixty-four percent of the women did not have evidence of HPV-16 infection at study entry: After a median follow-up of 17.4 months, significantly more cases of persistent HPV-16 infection were found in the placebo group than in the vaccine group (3.8 cases/100 woman-years vs. 0 cases). All 9 cases of HPV-16-related cervical intraepithelial neoplasia occurred in the placebo group. Among women who were infected with HPV-16 at study entry, rates of persistent HPV-16 infection were 6.3 and 0.6 cases/100 woman-years in the placebo and vaccine groups, respectively. No serious vaccine-related adverse events were reported, and symptoms that might have indicated adverse reactions were no more common in the vaccine group than in the placebo group.

Comment: The results of this large, well-designed study provide convincing evidence that this new vaccine can protect nearly perfectly against persistent HPV-16 infection and the preneoplastic conditions caused by such infection. This vaccine, or better yet, one that would protect against additional cancer-associated HPVs, might prove to be the most important intervention yet against cervical cancer.

— Anthony L. Komaroff, MD

Published in Journal Watch General Medicine December 3, 2002

Citation(s):

Koutsky LA et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 Nov 21; 347:1645-51.

Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002 Nov 21; 347:1703-5.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2002. Massachusetts Medical Society. All rights reserved.